GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concerns from U.S. and European regulators.
The post Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision appeared first on MedCity News.
